{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:12:45Z","timestamp":1794863565749,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Foundation (NRF) funded by the Korean government","award":["RS-2024-00440039"],"award-info":[{"award-number":["RS-2024-00440039"]}]},{"name":"the Korea Health Industry Development Institute","award":["RS-2022-KH130305"],"award-info":[{"award-number":["RS-2022-KH130305"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biol Eng"],"DOI":"10.1186\/s13036-026-00651-y","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:53:39Z","timestamp":1773158019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Seul-Gi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myungjee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Hyun","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Rok","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Ho","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2673-1509","authenticated-orcid":false,"given":"Yong-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"651_CR1","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","volume":"105","author":"P Leone","year":"2013","unstructured":"Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105:1172\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"651_CR2","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"651_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23:90\u2013105.","journal-title":"Nat Rev Immunol"},{"key":"651_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/pharmaceutics16091143","volume":"16","author":"S Douka","year":"2024","unstructured":"Douka S, Papamoschou V, Raimo M, Mastrobattista E, Caiazzo M. Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy. Pharmaceutics. 2024;16:1143.","journal-title":"Pharmaceutics"},{"key":"651_CR5","doi-asserted-by":"publisher","first-page":"605619","DOI":"10.3389\/fimmu.2020.605619","volume":"11","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH, Bear AS. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Front Immunol. 2020;11:605619.","journal-title":"Front Immunol"},{"key":"651_CR6","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.3390\/curroncol30040293","volume":"30","author":"R Balsano","year":"2023","unstructured":"Balsano R, Zanuso V, Pirozzi A, Rimassa L, Bozzarelli S. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. Curr Oncol. 2023;30:3871\u201385.","journal-title":"Curr Oncol"},{"key":"651_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/ijms17071090","volume":"17","author":"M Guo","year":"2016","unstructured":"Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, et al. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. Int J Mol Sci. 2016;17:1090.","journal-title":"Int J Mol Sci"},{"key":"651_CR8","doi-asserted-by":"publisher","first-page":"10373","DOI":"10.1038\/s41598-020-67187-z","volume":"10","author":"M Heby","year":"2020","unstructured":"Heby M, Karnevi E, Elebro J, Nodin B, Eberhard J, Saukkonen K, Hagstr\u00f6m J, Mustonen H, Sepp\u00e4nen H, Haglund C, et al. Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas. Sci Rep. 2020;10:10373.","journal-title":"Sci Rep"},{"key":"651_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1159\/000334465","volume":"11","author":"G Luo","year":"2011","unstructured":"Luo G, Long J, Qiu L, Liu C, Xu J, Yu X. Role of Epidermal Growth Factor Receptor Expression on Patient Survival in Pancreatic Cancer: A Meta-Analysis. Pancreatology. 2011;11:595\u2013600.","journal-title":"Pancreatology"},{"key":"651_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev-immunol-101819-074948","volume":"39","author":"AM Mujal","year":"2021","unstructured":"Mujal AM, Delconte RB, Sun JC. Natural Killer Cells: From Innate to Adaptive Features. Annu Rev Immunol. 2021;39:417\u201347.","journal-title":"Annu Rev Immunol"},{"key":"651_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16:430\u201341.","journal-title":"Cell Mol Immunol"},{"key":"651_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fimmu.2018.00441","volume":"9","author":"FM Wensveen","year":"2018","unstructured":"Wensveen FM, Jelen\u010di\u0107 V, Poli\u0107 B. NKG2D: A Master Regulator of Immune Cell Responsiveness. Front Immunol. 2018;9:441.","journal-title":"Front Immunol"},{"key":"651_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","volume":"235","author":"M Champsaur","year":"2010","unstructured":"Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235:267\u201385.","journal-title":"Immunol Rev"},{"key":"651_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/1479-5876-11-262","volume":"11","author":"YP Peng","year":"2013","unstructured":"Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, Jiang KR, Wu JL, Gao WT, Li Q, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med. 2013;11:262.","journal-title":"J Transl Med"},{"key":"651_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2019.00496","volume":"10","author":"SA Lim","year":"2019","unstructured":"Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496.","journal-title":"Front Immunol"},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1158\/1078-0432.CCR-05-0872","volume":"11","author":"C Germain","year":"2005","unstructured":"Germain C, Larbouret C, Cesson V, Donda A, Held W, Mach JP, P\u00e8legrin A, Robert B. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res. 2005;11:7516\u201322.","journal-title":"Clin Cancer Res"},{"key":"651_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/leu.2011.288","volume":"26","author":"C Kellner","year":"2012","unstructured":"Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia. 2012;26:830\u20134.","journal-title":"Leukemia"},{"key":"651_CR18","doi-asserted-by":"publisher","first-page":"105783","DOI":"10.1016\/j.pep.2020.105783","volume":"178","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Pang J, Yan F, Jiang Y, Cui D, Liu J, Jing L, Li Y, Liu Z, Tao L, et al. Production of a novel bispecific protein ULBP1\u00d7CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells. Protein Expr Purif. 2021;178:105783.","journal-title":"Protein Expr Purif"},{"key":"651_CR19","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2005-05-2177","volume":"107","author":"EP von Strandmann","year":"2006","unstructured":"von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, Simhadri VR, Draube A, Reiser M, Purr I, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006;107:1955\u201362.","journal-title":"Blood"},{"key":"651_CR20","doi-asserted-by":"publisher","first-page":"16445","DOI":"10.18632\/oncotarget.7501","volume":"7","author":"W Xie","year":"2016","unstructured":"Xie W, Liu F, Wang Y, Ren X, Wang T, Chen Z, Tang M, Sun F, Li Z, Wang M, Zhang J. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. Oncotarget. 2016;7:16445\u201361.","journal-title":"Oncotarget"},{"key":"651_CR21","doi-asserted-by":"publisher","first-page":"eaai8904","DOI":"10.1126\/scisignal.aai8904","volume":"10","author":"J Zuo","year":"2017","unstructured":"Zuo J, Willcox CR, Mohammed F, Davey M, Hunter S, Khan K, Antoun A, Katakia P, Croudace J, Inman C, et al. A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding. Sci Signal. 2017;10:eaai8904.","journal-title":"Sci Signal"},{"key":"651_CR22","doi-asserted-by":"publisher","first-page":"913215","DOI":"10.3389\/fimmu.2022.913215","volume":"13","author":"L Co\u00ebnon","year":"2022","unstructured":"Co\u00ebnon L, Villalba M. From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement. Front Immunol. 2022;13:913215.","journal-title":"Front Immunol"},{"key":"651_CR23","doi-asserted-by":"publisher","first-page":"1483884","DOI":"10.3389\/fonc.2024.1483884","volume":"14","author":"SK Nikkhoi","year":"2024","unstructured":"Nikkhoi SK, Li G, Hatefi A. Natural killer cell engagers for cancer immunotherapy. Front Oncol. 2024;14:1483884.","journal-title":"Front Oncol"},{"key":"651_CR24","doi-asserted-by":"publisher","first-page":"e0145349","DOI":"10.1371\/journal.pone.0145349","volume":"10","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, Kim YJ, Choi DK, Kim YS. Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening. PLoS ONE. 2015;10:e0145349.","journal-title":"PLoS ONE"},{"key":"651_CR25","doi-asserted-by":"publisher","first-page":"109755","DOI":"10.1016\/j.clim.2023.109755","volume":"255","author":"JH Kim","year":"2023","unstructured":"Kim JH, Kim DS, Park HS, Kim YS. Engineering bispecific T-cell engagers to deplete eosinophils for the treatment of severe eosinophilic asthma. Clin Immunol. 2023;255:109755.","journal-title":"Clin Immunol"},{"key":"651_CR26","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/1535-7163.MCT-13-0628","volume":"12","author":"HJ Choi","year":"2013","unstructured":"Choi HJ, Kim YJ, Lee S, Kim YS. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther. 2013;12:2748\u201359.","journal-title":"Mol Cancer Ther"},{"key":"651_CR27","doi-asserted-by":"publisher","first-page":"1034774","DOI":"10.3389\/fimmu.2022.1034774","volume":"13","author":"K Jung","year":"2022","unstructured":"Jung K, Yoo S, Kim JE, Kim W, Kim YS. Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy. Front Immunol. 2022;13:1034774.","journal-title":"Front Immunol"},{"key":"651_CR28","doi-asserted-by":"publisher","first-page":"eaay2174","DOI":"10.1126\/sciadv.aay2174","volume":"6","author":"SM Shin","year":"2020","unstructured":"Shin SM, Kim JS, Park SW, Jun SY, Kweon HJ, Choi DK, Lee D, Cho YB, Kim YS. Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth. Sci Adv. 2020;6:eaay2174.","journal-title":"Sci Adv"},{"key":"651_CR29","doi-asserted-by":"publisher","first-page":"134668","DOI":"10.1016\/j.ijbiomac.2024.134668","volume":"278","author":"HJ Lee","year":"2024","unstructured":"Lee HJ, Chae BH, Ko DH, Lee SG, Yoon SR, Kim DS, Kim YS. Enhancing the cytotoxicity of immunotoxins by facilitating their dissociation from target receptors under the reducing conditions of the endocytic pathway. Int J Biol Macromol. 2024;278:134668.","journal-title":"Int J Biol Macromol"},{"key":"651_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bbrc.2022.04.110","volume":"612","author":"SW Park","year":"2022","unstructured":"Park SW, Lee DS, Kim YS. Engineering a U-box of E3 ligase E4B through yeast surface display-based functional screening generates a variant with enhanced ubiquitin ligase activity. Biochem Biophys Res Commun. 2022;612:147\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"651_CR31","doi-asserted-by":"publisher","first-page":"15820","DOI":"10.3390\/ijms232415820","volume":"23","author":"SY Jun","year":"2022","unstructured":"Jun SY, Kim DS, Kim YS. Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity. Int J Mol Sci. 2022;23:15820.","journal-title":"Int J Mol Sci"},{"key":"651_CR32","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/0008-5472.CAN-12-2893","volume":"73","author":"SA Lim","year":"2013","unstructured":"Lim SA, Kim TJ, Lee JE, Sonn CH, Kim K, Kim J, Choi JG, Choi IK, Yun CO, Kim JH, et al. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res. 2013;73:2598\u2013607.","journal-title":"Cancer Res"},{"key":"651_CR33","doi-asserted-by":"publisher","first-page":"593748","DOI":"10.3389\/fimmu.2020.593748","volume":"11","author":"J-E Kim","year":"2021","unstructured":"Kim J-E, Lee D-H, Jung K, Kim E-J, Choi Y, Park H-S, Kim Y-S. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity. Front Immunol. 2021;11:593748.","journal-title":"Front Immunol"},{"key":"651_CR34","doi-asserted-by":"publisher","first-page":"113727","DOI":"10.1016\/j.jconrel.2025.113727","volume":"382","author":"DS Kim","year":"2025","unstructured":"Kim DS, Kim SE, Byeon JS, Lee HJ, Kim JW, Kim H, Chae BH, Ko DH, Lee SG, Yoon SR, et al. Engineering IgG antibodies for intracellular targeting and drug delivery. J Control Release. 2025;382:113727.","journal-title":"J Control Release"},{"key":"651_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00262-024-03795-2","volume":"73","author":"A Herault","year":"2024","unstructured":"Herault A, Mak J, de la Cruz-Chuh J, Dillon MA, Ellerman D, Go M, Cosino E, Clark R, Carson E, Yeung S, et al. NKG2D-bispecific enhances NK and CD8\u2009+\u2009T cell antitumor immunity. Cancer Immunol Immunother. 2024;73:209.","journal-title":"Cancer Immunol Immunother"},{"key":"651_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1073\/pnas.83.3.710","volume":"83","author":"CA Hutchison","year":"1986","unstructured":"Hutchison CA 3rd, Nordeen SK, Vogt K, Edgell MH. A complete library of point substitution mutations in the glucocorticoid response element of mouse mammary tumor virus. Proc Natl Acad Sci U S A. 1986;83:710\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"651_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/bp970144q","volume":"14","author":"ET Boder","year":"1998","unstructured":"Boder ET, Wittrup KD. Optimal screening of surface-displayed polypeptide libraries. Biotechnol Prog. 1998;14:55\u201362.","journal-title":"Biotechnol Prog"},{"key":"651_CR38","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4014\/jmb.1401.01002","volume":"24","author":"DS Baek","year":"2014","unstructured":"Baek DS, Kim YS. Construction of a large synthetic human Fab antibody library on yeast cell surface by optimized yeast mating. J Microbiol Biotechnol. 2014;24:408\u201320.","journal-title":"J Microbiol Biotechnol"},{"key":"651_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12943-022-01574-0","volume":"21","author":"K Jung","year":"2022","unstructured":"Jung K, Son MJ, Lee SY, Kim JA, Ko DH, Yoo S, Kim CH, Kim YS. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8(+) T cells for cancer immunotherapy. Mol Cancer. 2022;21:102.","journal-title":"Mol Cancer"},{"key":"651_CR40","doi-asserted-by":"publisher","first-page":"e13022","DOI":"10.1200\/jco.2011.29.15_suppl.e13022","volume":"29","author":"MB Topper","year":"2011","unstructured":"Topper MB, Tonra JR, Pytowski B, Eastman SW. Differentiation between the EGFR antibodies necitumumab, cetuximab, and panitumumab: Antibody internalization and EGFR degradation. J Clin Oncol. 2011;29:e13022.","journal-title":"J Clin Oncol"},{"key":"651_CR41","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.2147\/OTT.S114039","volume":"9","author":"C Genova","year":"2016","unstructured":"Genova C, Hirsch FR. Clinical potential of necitumumab in non-small cell lung carcinoma. Onco Targets Ther. 2016;9:5427\u201337.","journal-title":"Onco Targets Ther"},{"key":"651_CR42","doi-asserted-by":"publisher","first-page":"e107739","DOI":"10.15252\/embj.2021107739","volume":"41","author":"J Fan","year":"2022","unstructured":"Fan J, Shi J, Zhang Y, Liu J, An C, Zhu H, Wu P, Hu W, Qin R, Yao D, et al. NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes. Embo j. 2022;41:e107739.","journal-title":"Embo j"},{"key":"651_CR43","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625.","journal-title":"EBioMedicine"},{"key":"651_CR44","doi-asserted-by":"publisher","first-page":"2315640","DOI":"10.1080\/19420862.2024.2315640","volume":"16","author":"AS Boje","year":"2024","unstructured":"Boje AS, Pekar L, Koep K, Lipinski B, Rabinovich B, Evers A, Gehlert CL, Krohn S, Xiao Y, Krah S, et al. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers. MAbs. 2024;16:2315640.","journal-title":"MAbs"},{"key":"651_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4049\/jimmunol.2001004","volume":"206","author":"L Pekar","year":"2021","unstructured":"Pekar L, Klausz K, Busch M, Valldorf B, Kolmar H, Wesch D, Oberg HH, Krohn S, Boje AS, Gehlert CL, et al. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement. J Immunol. 2021;206:225\u201336.","journal-title":"J Immunol"},{"key":"651_CR46","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","volume":"11","author":"K Ellwanger","year":"2019","unstructured":"Ellwanger K, Reusch U, Fucek I, Wingert S, Ross T, M\u00fcller T, Schniegler-Mattox U, Haneke T, Rajkovic E, Koch J, et al. Redirected optimized cell killing (ROCK\u00ae): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. MAbs. 2019;11:899\u2013918.","journal-title":"MAbs"},{"key":"651_CR47","doi-asserted-by":"publisher","first-page":"1845424","DOI":"10.1080\/2162402X.2020.1845424","volume":"9","author":"F Marcon","year":"2020","unstructured":"Marcon F, Zuo J, Pearce H, Nicol S, Margielewska-Davies S, Farhat M, Mahon B, Middleton G, Brown R, Roberts KJ, Moss P. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunology. 2020;9:1845424.","journal-title":"Oncoimmunology"},{"key":"651_CR48","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.1038\/s41467-025-61196-0","volume":"16","author":"V Picant","year":"2025","unstructured":"Picant V, Revol-Bauz L, Tonon L, Casini T, Voissiere A, Poujol D, Picard E, Rodriguez C, Degletagne C, Sible E, et al. Interleukin-35 impairs human NK cell effector functions and induces their ILC1-like conversion with tissue residency features. Nat Commun. 2025;16:6135.","journal-title":"Nat Commun"},{"key":"651_CR49","doi-asserted-by":"publisher","first-page":"2208697","DOI":"10.1080\/19420862.2023.2208697","volume":"15","author":"KA Whalen","year":"2023","unstructured":"Whalen KA, Rakhra K, Mehta NK, Steinle A, Michaelson JS, Baeuerle PA. Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors. MAbs. 2023;15:2208697.","journal-title":"MAbs"},{"key":"651_CR50","first-page":"2064","volume":"9","author":"H Liu","year":"2019","unstructured":"Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z. Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 2019;9:2064\u201378.","journal-title":"Am J Cancer Res"},{"key":"651_CR51","first-page":"1079","volume":"12","author":"G Tan","year":"2023","unstructured":"Tan G, Spillane KM, Maher J. The Role and Regulation of the NKG2D\/NKG2D Ligand System in Cancer. Biology (Basel). 2023;12:1079.","journal-title":"Biology (Basel)"},{"key":"651_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","volume":"51","author":"P Dhar","year":"2018","unstructured":"Dhar P, Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55\u201361.","journal-title":"Curr Opin Immunol"},{"key":"651_CR53","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/0008-5472.CAN-25-0820","volume":"86","author":"JD Stone","year":"2025","unstructured":"Stone JD, Fish K, Ashok D, McKay LM, Akhand SS, DiGiammarino E, Inzunza HD, Palma JP, Cosgrove C, Ellis PA, et al. ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing Tumors. Cancer Res. 2025;86:746\u201358.","journal-title":"Cancer Res"},{"key":"651_CR54","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1002\/ctm2.70046","volume":"14","author":"A Zhu","year":"2024","unstructured":"Zhu A, Bai Y, Nan Y, Ju D. Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy. Clin Transl Med. 2024;14:e70046.","journal-title":"Clin Transl Med"},{"key":"651_CR55","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12967-025-07650-5","volume":"24","author":"H Wei","year":"2026","unstructured":"Wei H, Xiang L, Zhou Y, Huang Y, Liu L, Cao D. Targeting NKG2D\/NKG2DL axis in cancer immunotherapy: mechanisms and therapeutic applications. J Translational Med. 2026;24:126.","journal-title":"J Translational Med"},{"key":"651_CR56","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1073\/pnas.92.11.5042","volume":"92","author":"TW McKeithan","year":"1995","unstructured":"McKeithan TW. Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci U S A. 1995;92:5042\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"651_CR57","doi-asserted-by":"publisher","first-page":"gzae013","DOI":"10.1093\/protein\/gzae013","volume":"37","author":"RB Lee","year":"2024","unstructured":"Lee RB, Maddineni S, Landry M, Diaz C, Tashfeen A, Yamada-Hunter SA, Mackall CL, Beinat C, Sunwoo JB, Cochran JR. An engineered NKp46 antibody for construction of multi-specific NK cell engagers. Protein Eng Des Sel. 2024;37:gzae013.","journal-title":"Protein Eng Des Sel"},{"key":"651_CR58","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4161\/mabs.28591","volume":"6","author":"U Reusch","year":"2014","unstructured":"Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M, Zhukovsky EA. A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30\u2009+\u2009tumor cells. MAbs. 2014;6:728\u201339.","journal-title":"MAbs"},{"key":"651_CR59","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell. 2020;38:788\u2013802.","journal-title":"Cancer Cell"},{"key":"651_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/sji.12072","volume":"78","author":"G Chitadze","year":"2013","unstructured":"Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol. 2013;78:120\u20139.","journal-title":"Scand J Immunol"},{"key":"651_CR61","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"651_CR62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/apc.2020.03.03","volume":"3","author":"M He","year":"2020","unstructured":"He M, Henderson M, Muth S, Murphy A, Zheng L. Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma. Ann Pancreat Cancer. 2020;3:7.","journal-title":"Ann Pancreat Cancer"},{"key":"651_CR63","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/cancers13030440","volume":"13","author":"TND Pham","year":"2021","unstructured":"Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, Trevino JG, Bentrem DJ, Munshi HG. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers (Basel). 2021;13:400.","journal-title":"Cancers (Basel)"},{"key":"651_CR64","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/cmi.2017.161","volume":"15","author":"K Prajapati","year":"2018","unstructured":"Prajapati K, Perez C, Rojas LBP, Burke B, Guevara-Patino JA. Functions of NKG2D in CD8(+) T cells: an opportunity for immunotherapy. Cell Mol Immunol. 2018;15:470\u20139.","journal-title":"Cell Mol Immunol"},{"key":"651_CR65","doi-asserted-by":"publisher","first-page":"1227572","DOI":"10.3389\/fimmu.2023.1227572","volume":"14","author":"S Lutz","year":"2023","unstructured":"Lutz S, Klausz K, Albici A-M, Ebinger L, Sellmer L, Teipel H, Frenzel A, Langner A, Winterberg D, Krohn S, et al. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells. Front Immunol. 2023;14:1227572.","journal-title":"Front Immunol"}],"container-title":["Journal of Biological Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13036-026-00651-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-026-00651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-026-00651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:03:06Z","timestamp":1776387786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13036-026-00651-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1186\/s13036-026-00651-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8589580\/v1","asserted-by":"object"}]},"ISSN":["1754-1611"],"issn-type":[{"value":"1754-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The blood sampling procedure was reviewed and approved by the Institutional Review Board of Ajou University (AjouIRB202502-HM-001). All healthy donors provided written informed consent before the blood samples were collected. All animal experiments were approved by the Animal and Ethics Review Committee of Ajou University (approval ID: 2023\u20130096) and conducted in accordance with the guidelines of the Animal Care and Use Committee of Ajou University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}